IS5864A - Ný hýdratform af alendrónatnatríum, aðferðir við framleiðslu þeirra og lyfjablöndur þeirra - Google Patents

Ný hýdratform af alendrónatnatríum, aðferðir við framleiðslu þeirra og lyfjablöndur þeirra

Info

Publication number
IS5864A
IS5864A IS5864A IS5864A IS5864A IS 5864 A IS5864 A IS 5864A IS 5864 A IS5864 A IS 5864A IS 5864 A IS5864 A IS 5864A IS 5864 A IS5864 A IS 5864A
Authority
IS
Iceland
Prior art keywords
new
alendronate sodium
manufacturing
methods
pharmaceutical formulations
Prior art date
Application number
IS5864A
Other languages
English (en)
Icelandic (is)
Inventor
Finkelstein Nina
Lidor-Hadas Ramy
Aronhime Judith
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of IS5864A publication Critical patent/IS5864A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839Polyphosphonic acids
    • C07F9/3873Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IS5864A 1998-08-27 2001-02-26 Ný hýdratform af alendrónatnatríum, aðferðir við framleiðslu þeirra og lyfjablöndur þeirra IS5864A (is)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9831398P 1998-08-27 1998-08-27
US12974399P 1999-04-16 1999-04-16
US14446199P 1999-07-19 1999-07-19
PCT/US1999/019838 WO2000012517A1 (en) 1998-08-27 1999-08-27 Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
IS5864A true IS5864A (is) 2001-02-26

Family

ID=27378576

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5864A IS5864A (is) 1998-08-27 2001-02-26 Ný hýdratform af alendrónatnatríum, aðferðir við framleiðslu þeirra og lyfjablöndur þeirra

Country Status (30)

Country Link
US (2) US6281381B1 (https=)
EP (1) EP1107974B1 (https=)
JP (2) JP2002523514A (https=)
KR (2) KR20070034132A (https=)
AT (1) ATE334993T1 (https=)
AU (1) AU5698899A (https=)
BG (1) BG65329B1 (https=)
BR (1) BR9913472A (https=)
CA (1) CA2341459A1 (https=)
CZ (1) CZ2001629A3 (https=)
DE (1) DE69932620T2 (https=)
DK (1) DK1107974T3 (https=)
EA (1) EA002739B1 (https=)
EE (1) EE04552B1 (https=)
ES (1) ES2270613T3 (https=)
HR (1) HRP20010129A2 (https=)
HU (1) HUP0203078A3 (https=)
IL (1) IL141423A (https=)
IS (1) IS5864A (https=)
LT (1) LT4888B (https=)
LV (1) LV12720B (https=)
NO (1) NO20010957L (https=)
NZ (1) NZ510682A (https=)
PL (1) PL346347A1 (https=)
PT (1) PT1107974E (https=)
RO (1) RO122854B1 (https=)
SI (1) SI20581B (https=)
SK (1) SK2482001A3 (https=)
WO (1) WO2000012517A1 (https=)
YU (1) YU14701A (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1406910B1 (fr) * 2001-07-16 2010-01-13 Universite Paris 13 Procedes de preparation de derives de bisphosphonates
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
CA2470495A1 (en) * 2001-12-24 2003-07-17 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
ITMI20020146A1 (it) * 2002-01-29 2003-07-29 Lyogen Ltd Alendronato monosodico amorfo e processo per la sua preparazione
AU2003226148A1 (en) * 2002-04-05 2003-10-27 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20080249068A1 (en) * 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US20050113343A1 (en) * 2003-10-14 2005-05-26 Pliva - Research And Development Ltd. Solid-state form of alendronate sodium and preparation thereof
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
DK2283825T3 (da) 2004-05-24 2022-06-27 Theramex Hq Uk Ltd Enterisk fast oral doseringsform af en bisfosfonat indeholdende et chelateringsmiddel
CZ296937B6 (cs) * 2004-09-02 2006-07-12 Zentiva, A. S Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
AU2005302500B2 (en) * 2004-10-29 2008-11-27 Sandoz Ag Processes for preparing glatiramer
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
CZ297262B6 (cs) * 2004-12-28 2006-10-11 Zentiva, A. S. Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
US8003820B2 (en) * 2005-10-20 2011-08-23 Dr. Reddy's Laboratories Limited Process for preparing bisphosphonic acids
AR058168A1 (es) * 2005-11-07 2008-01-23 Merck & Co Inc Sintesis del alendronato de sodio trihidratado
NZ598071A (en) * 2006-10-27 2013-08-30 Signal Pharm Llc Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
ES2392890T3 (es) * 2006-11-22 2012-12-14 Eisai R&D Management Co., Ltd. Sal sódica de un compuesto disacarídico, procedimiento para la producción de la misma y uso de la misma
US20090076144A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bazedoxifene
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090170815A1 (en) * 2007-12-28 2009-07-02 Roxane Laboratories Incorporated. Alendronate oral liquid formulations
WO2011054182A1 (zh) * 2009-11-03 2011-05-12 Liu Li 丹参酮ⅱa磺酸钠水合物及其制备方法和用途
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de) * 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4711800A (en) * 1985-06-06 1987-12-08 Divincenzo Maureen Needlecraft with metallic substrate
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5159108A (en) 1990-09-18 1992-10-27 Merck & Co., Inc. Process for preparing an antihypercalcemic agent
US5039819A (en) * 1990-09-18 1991-08-13 Merck & Co., Inc. Diphosphonate intermediate for preparing an antihypercalcemic agent
WO1996039149A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Anhydrous alendronate monosodium salt formulations
CA2221844A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Disodium alendronate formulations

Also Published As

Publication number Publication date
LV12720B (en) 2002-02-20
EA200100184A1 (ru) 2001-10-22
US6281381B1 (en) 2001-08-28
RO122854B1 (ro) 2010-03-30
BR9913472A (pt) 2002-03-05
ATE334993T1 (de) 2006-08-15
SK2482001A3 (en) 2002-01-07
BG65329B1 (bg) 2008-02-29
NO20010957L (no) 2001-04-26
WO2000012517A1 (en) 2000-03-09
JP2009143955A (ja) 2009-07-02
LT2001016A (en) 2001-10-25
PL346347A1 (en) 2002-02-11
DK1107974T3 (da) 2006-10-30
EE04552B1 (et) 2005-10-17
NO20010957D0 (no) 2001-02-26
KR20070034132A (ko) 2007-03-27
BG105292A (en) 2001-12-29
KR20010079701A (ko) 2001-08-22
EP1107974A4 (en) 2001-09-26
HUP0203078A2 (hu) 2003-01-28
IL141423A0 (en) 2002-03-10
CA2341459A1 (en) 2000-03-09
DE69932620T2 (de) 2006-12-14
DE69932620D1 (de) 2006-09-14
LV12720A (lv) 2001-09-20
US6696601B2 (en) 2004-02-24
LT4888B (lt) 2002-02-25
WO2000012517A9 (en) 2000-07-13
AU5698899A (en) 2000-03-21
EP1107974A1 (en) 2001-06-20
HUP0203078A3 (en) 2005-01-28
IL141423A (en) 2005-09-25
NZ510682A (en) 2003-09-26
US20030065214A1 (en) 2003-04-03
HRP20010129A2 (en) 2005-04-30
SI20581B (sl) 2008-06-30
EA002739B1 (ru) 2002-08-29
PT1107974E (pt) 2006-10-31
YU14701A (sh) 2003-01-31
CZ2001629A3 (cs) 2001-08-15
ES2270613T3 (es) 2007-04-01
EE200100126A (et) 2002-06-17
SI20581A (sl) 2001-12-31
EP1107974B1 (en) 2006-08-02
JP2002523514A (ja) 2002-07-30

Similar Documents

Publication Publication Date Title
IS5864A (is) Ný hýdratform af alendrónatnatríum, aðferðir við framleiðslu þeirra og lyfjablöndur þeirra
DK1233770T3 (da) Phosphonatforbindelser
NO952863D0 (no) Fluoxetin-farmasöytiske sammensetninger
NO20012158L (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
AU7642001A (en) Novel $G(Y) crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same.
HUP0400781A3 (en) Process for the crystallization of (r)- or (s)-lansoprazole, the prepared crystalls and pharmaceutical compositions containing them and their use
ATE329587T1 (de) Zusammensetzungen zur verwendung bei der behandlung der osteoporose und/oder der entzündlichen gelenkerkrankungen
NO20003530D0 (no) Vedvarende frigivelsessammensetning, metode for dens produksjon og anvendelse derav
AU7641801A (en) Alpha crystalline form of perindopril tert-butylamine salt
NO20030050D0 (no) Ny <beta>-krystallinsk form av perindopril tert- butylaminsalt, fremgangsmåte for dens fremstilling og farmasöytiske sammensetningerinneholdende den
HUP0401141A3 (en) Crystalline forms of fluvastatin sodium, process for their preparation and pharmaceutical compositions containing them
NO20050664L (no) 2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer
PT1051159E (pt) Composicoes farmaceuticas solidas contendo miltefosina para administracao oral no tratamento de leishmaniose
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
TR200200278T2 (tr) Kalsilitik bileşimler
DE69939559D1 (de) Methode zur Beschleunigung der Schleimauflöserate
CY1106711T1 (el) Υποκατεστημενα παραγωγα προπανο-1,3-διαμινης και η φαρμακευτικη χρηση τους
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
EP1702924A3 (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
BR9714973A (pt) Formulações de goma de mascar incluindo aspartame e bicarbonato de sódio
CR20120385A (es) Nuevos pirrolocarbazoles fusionados (divisional exp. 8519)
ITMI981691A1 (it) Composizioni farmaceutiche atte alla sommistrazione per via transdermale di apomorfina
MY118194A (en) Pharmaceutical compositions for use in inhibiting bone resorption